Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,813 followers
The tirzepatide dose remains the same
How do I choose the right supplement for me
Is L-Carnitine safe to feed alongside other supplements or medications
When Increased Urination May Indicate a Problem Whilst increased urination is not a characteristic side effect of Ozempic itself, changes in urinary patterns warrant clinical attention as they may signal underlying conditions requiring investigation or management adjustments
doi: 10.1016/j.cell.2008.01.017 85 YokoteR.SatoM.MatsubaraS.OhyeH.NiimiM.MuraoK.et al
